vs
Side-by-side financial comparison of CENTERSPACE (CSR) and Fulgent Genetics, Inc. (FLGT). Click either name above to swap in a different company.
Fulgent Genetics, Inc. is the larger business by last-quarter revenue ($71.1M vs $65.1M, roughly 1.1× CENTERSPACE). On growth, CENTERSPACE posted the faster year-over-year revenue change (-3.0% vs -3.2%). Over the past eight quarters, Fulgent Genetics, Inc.'s revenue compounded faster (0.1% CAGR vs 0.0%).
Centerspace is a real estate investment company specializing in the ownership, operation, and development of high-quality multifamily residential properties. Its core operating markets cover the U.S. Midwest and Mountain West regions, serving diverse renter segments with both affordable and premium housing options, while focusing on tenant experience and long-term asset value growth.
Fulgent Genetics, Inc. is a molecular diagnostics technology firm that develops and offers genetic testing services including carrier screening, oncology testing, infectious disease detection, and hereditary condition analysis, serving clinical providers, pharma firms, research institutions and public health groups primarily in North America.
CSR vs FLGT — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $65.1M | $71.1M |
| Net Profit | $-15.0M | — |
| Gross Margin | — | 30.2% |
| Operating Margin | — | 21.1% |
| Net Margin | -23.0% | — |
| Revenue YoY | -3.0% | -3.2% |
| Net Profit YoY | -258.1% | — |
| EPS (diluted) | $-0.49 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $65.1M | $71.1M | ||
| Q4 25 | $66.6M | $83.3M | ||
| Q3 25 | $71.4M | $84.1M | ||
| Q2 25 | $68.5M | $81.8M | ||
| Q1 25 | $67.1M | $73.5M | ||
| Q4 24 | $66.4M | $76.2M | ||
| Q3 24 | $65.0M | $71.7M | ||
| Q2 24 | $65.0M | $71.0M |
| Q1 26 | $-15.0M | — | ||
| Q4 25 | $-18.4M | $-23.4M | ||
| Q3 25 | $53.8M | $-6.6M | ||
| Q2 25 | $-14.5M | $-19.0M | ||
| Q1 25 | $-3.7M | $-11.5M | ||
| Q4 24 | $-5.1M | $-5.9M | ||
| Q3 24 | $-1.0M | $-14.6M | ||
| Q2 24 | $-1.3M | $-8.7M |
| Q1 26 | — | 30.2% | ||
| Q4 25 | 96.5% | 39.1% | ||
| Q3 25 | 96.5% | 42.2% | ||
| Q2 25 | 96.5% | 42.1% | ||
| Q1 25 | 96.4% | 38.6% | ||
| Q4 24 | 96.5% | 41.8% | ||
| Q3 24 | 96.6% | 37.3% | ||
| Q2 24 | 96.6% | 37.3% |
| Q1 26 | — | 21.1% | ||
| Q4 25 | -15.9% | -43.5% | ||
| Q3 25 | — | -18.3% | ||
| Q2 25 | -9.9% | -24.1% | ||
| Q1 25 | 7.1% | -26.9% | ||
| Q4 24 | 4.3% | -21.2% | ||
| Q3 24 | 9.8% | -23.8% | ||
| Q2 24 | 11.1% | -26.6% |
| Q1 26 | -23.0% | — | ||
| Q4 25 | -27.7% | -28.1% | ||
| Q3 25 | 75.3% | -7.9% | ||
| Q2 25 | -21.2% | -23.2% | ||
| Q1 25 | -5.6% | -15.7% | ||
| Q4 24 | -7.6% | -7.7% | ||
| Q3 24 | -1.6% | -20.4% | ||
| Q2 24 | -2.0% | -12.3% |
| Q1 26 | $-0.49 | $0.04 | ||
| Q4 25 | $-1.08 | — | ||
| Q3 25 | $3.19 | — | ||
| Q2 25 | $-0.87 | — | ||
| Q1 25 | $-0.22 | — | ||
| Q4 24 | $-0.31 | — | ||
| Q3 24 | $-0.40 | — | ||
| Q2 24 | $-0.19 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.6M | $23.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $695.0M | — |
| Total Assets | $1.9B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $7.6M | $23.4M | ||
| Q4 25 | $12.8M | $50.2M | ||
| Q3 25 | $12.9M | $117.6M | ||
| Q2 25 | $12.4M | $87.9M | ||
| Q1 25 | $11.9M | $67.3M | ||
| Q4 24 | $12.0M | $55.1M | ||
| Q3 24 | $14.5M | $58.0M | ||
| Q2 24 | $14.3M | $65.1M |
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $955.5M | — | ||
| Q4 24 | $955.4M | — | ||
| Q3 24 | $921.3M | — | ||
| Q2 24 | $931.7M | — |
| Q1 26 | $695.0M | — | ||
| Q4 25 | $719.2M | $1.1B | ||
| Q3 25 | $748.6M | $1.1B | ||
| Q2 25 | $710.1M | $1.1B | ||
| Q1 25 | $636.8M | $1.1B | ||
| Q4 24 | $752.0M | $1.1B | ||
| Q3 24 | $672.5M | $1.1B | ||
| Q2 24 | $680.7M | $1.1B |
| Q1 26 | $1.9B | $1.2B | ||
| Q4 25 | $1.9B | $1.2B | ||
| Q3 25 | $2.1B | $1.2B | ||
| Q2 25 | $2.0B | $1.2B | ||
| Q1 25 | $1.9B | $1.2B | ||
| Q4 24 | $1.9B | $1.2B | ||
| Q3 24 | $1.9B | $1.2B | ||
| Q2 24 | $1.9B | $1.2B |
| Q1 26 | — | — | ||
| Q4 25 | 1.42× | — | ||
| Q3 25 | 1.53× | — | ||
| Q2 25 | 1.57× | — | ||
| Q1 25 | 1.50× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.37× | — | ||
| Q2 24 | 1.37× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
